Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nutrients ; 12(11)2020 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-33202638

RESUMEN

BACKGROUND: Optimizing the refeeding of patients with anorexia nervosa remains important to limit somatic complications of malnutrition, as well as to avoid disease relapses by targeting persistent mood and intestinal disorders. We aimed to evaluate the effects of glutamine (Gln) and branched-chain amino acids (BCAA) supplementation during refeeding in activity-based anorectic (ABA) mice. METHOD: Male C57Bl/6 mice were randomized in control and ABA groups. Once ABA-induced malnutrition was established, mice were progressively refed or not. Refed mice had free access to drinking water supplemented or not with 1% Gln or 2.5% BCAA for 10 days. RESULTS: A progressive refeeding was associated with a partial restoration of body weight and lean mass, while a fat mass rebound was observed. In addition, refeeding restored glucose and leptin. Gln did not affect these parameters, while BCAA tended to increase body weight, fat mass, and glycaemia. In the colon, refeeding improved total protein synthesis and restored the LC3II/LC3I ratio, a marker of autophagy. Gln supplementation enhanced colonic protein synthesis, which was associated with an increased p-p70S6kinase/p70S6kinase ratio, whereas these effects were blunted by BCCA supplementation. CONCLUSIONS: In ABA mice, Gln and BCAA supplementations during a progressive refeeding fail to restore body weight and lean mass. However, Gln supplementation improves total colonic protein synthesis conversely to BCAA. Further studies are needed to decipher the underlying mechanisms involved in these opposite results.


Asunto(s)
Aminoácidos de Cadena Ramificada/administración & dosificación , Anorexia Nerviosa/metabolismo , Suplementos Dietéticos , Glutamina/administración & dosificación , Desnutrición/metabolismo , Animales , Anorexia Nerviosa/fisiopatología , Composición Corporal , Colon/fisiopatología , Conducta Alimentaria , Masculino , Desnutrición/fisiopatología , Ratones , Ratones Endogámicos C57BL , Permeabilidad , Biosíntesis de Proteínas
2.
Nutrients ; 11(9)2019 Sep 16.
Artículo en Inglés | MEDLINE | ID: mdl-31527523

RESUMEN

: Undernutrition is a major public health problem leading to 1 in 5 of all deaths in children under 5 years. Undernutrition leads to growth stunting and/or wasting and is often associated with environmental enteric dysfunction (EED). EED mechanisms leading to growth failure include intestinal hyperpermeability, villus blunting, malabsorption and gut inflammation. As non-invasive methods for investigating gut function in undernourished children are limited, pre-clinical models are relevant to elucidating the pathophysiological processes involved in undernutrition and EED, and to identifying novel therapeutic strategies. In many published models, undernutrition was induced using protein or micronutrient deficient diets, but these experimental models were not associated with EED. Enteropathy models mainly used gastrointestinal injury triggers. These models are presented in this review. We found only a few studies investigating the combination of undernutrition and enteropathy. This highlights the need for further developments to establish an experimental model reproducing the impact of undernutrition and enteropathy on growth, intestinal hyperpermeability and inflammation, that could be suitable for preclinical evaluation of innovative therapeutic intervention.


Asunto(s)
Trastornos de la Nutrición del Niño/fisiopatología , Enteritis/fisiopatología , Trastornos de la Nutrición del Lactante/fisiopatología , Síndromes de Malabsorción/fisiopatología , Desnutrición/fisiopatología , Estado Nutricional , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Trastornos de la Nutrición del Niño/metabolismo , Trastornos de la Nutrición del Niño/microbiología , Preescolar , Modelos Animales de Enfermedad , Metabolismo Energético , Enteritis/metabolismo , Enteritis/microbiología , Microbioma Gastrointestinal , Humanos , Lactante , Trastornos de la Nutrición del Lactante/metabolismo , Trastornos de la Nutrición del Lactante/microbiología , Fenómenos Fisiológicos Nutricionales del Lactante , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Mucosa Intestinal/fisiopatología , Síndromes de Malabsorción/metabolismo , Síndromes de Malabsorción/microbiología , Desnutrición/metabolismo , Desnutrición/microbiología , Permeabilidad
3.
Nutrients ; 11(6)2019 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-31208031

RESUMEN

BACKGROUND: During activity-based anorexia (ABA) in mice, enhanced paracellular permeability and reduced protein synthesis have been shown in the colon while the gut-brain axis has received increasing attention in the regulation of intestinal and mood disorders that frequently occur during anorexia nervosa, a severe eating disorder for which there is no specific treatment. In the present study, we assessed the effects of oral glutamine (Gln) or branched-chain amino acids (BCAA) supplementation during ABA to target intestinal functions, body composition and feeding behavior. METHODS: C57BL/6 male mice were randomized in Control (CTRL) and ABA groups. After ABA induction, mice received, or not, either 1% Gln or 2.5% BCAA (Leu, Ile, Val) for one week in drinking water. RESULTS: Neither Gln nor BCAA supplementation affected body weight and body composition, while only Gln supplementation slightly increased food intake. ABA mice exhibited increased paracellular permeability and reduced protein synthesis in the colonic mucosa. Oral Gln restored colonic paracellular permeability and protein synthesis and increased the mucin-2 mRNA level, whereas BCAA did not affect colonic parameters. CONCLUSION: In conclusion, oral Gln specifically improves colonic response during ABA. These data should be further confirmed in AN patients.


Asunto(s)
Aminoácidos de Cadena Ramificada/farmacología , Anorexia/tratamiento farmacológico , Suplementos Dietéticos , Glutamina/farmacología , Mucosa Intestinal/efectos de los fármacos , Animales , Anorexia/fisiopatología , Composición Corporal/efectos de los fármacos , Colon/efectos de los fármacos , Colon/fisiopatología , Conducta Alimentaria/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Permeabilidad/efectos de los fármacos , Biosíntesis de Proteínas/efectos de los fármacos
4.
Mediators Inflamm ; 2018: 8430614, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29670469

RESUMEN

BACKGROUND: Inflammatory bowel diseases (IBD) occurred in genetically predisposed people exposed to environmental triggers. Diet has long been suspected to contribute to the development of IBD. Supplementation with n-3 polyunsaturated fatty acids (PUFA) protects against intestinal inflammation in rodent models while clinical trials showed no benefits. We hypothesized that intervention timing is crucial and dietary fatty acid pattern may influence intestinal environment to modify inflammation genesis. The aim of this study was to evaluate the dietary effect of PUFA composition on intestinal inflammation. METHODS: Animals received diet varying in their PUFA composition for four weeks before TNBS-induced colitis. Colon inflammatory markers and gut barrier function parameters were assessed. Inflammatory pathway PCR arrays were determined. RESULTS: n-3 diet significantly decreased colon iNOS, COX-2 expression, IL-6 production, and LTB4 production but tended to decrease colon TNFα production (P = 0.0617) compared to control diet. Tight junction protein (claudin-1, occludin) expressions and MUC2 and TFF3 mRNA levels were not different among groups. n-9 diet also decreased colon IL-6 production (P < 0.05). CONCLUSIONS: Dietary n-3 PUFA influence colitis development by attenuating inflammatory markers. Further research is required to better define dietary advice with a scientific rationale.


Asunto(s)
Colitis/tratamiento farmacológico , Ácidos Grasos Omega-3/uso terapéutico , Animales , Claudina-1/metabolismo , Ciclooxigenasa 2/metabolismo , Modelos Animales de Enfermedad , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Interleucina-6/metabolismo , Leucotrieno B4/metabolismo , Masculino , Óxido Nítrico Sintasa de Tipo II/metabolismo , Ocludina/metabolismo , Ratas , Ratas Sprague-Dawley , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA